Last reviewed · How we verify
Tinostamustinein
Tinostamustinein is a Small molecule drug developed by Royal Marsden NHS Foundation Trust. It is currently in discontinued development.
Tinostamustine is being studied in a Phase Ib clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma. The trial combines Tinostamustine with Rituximab and Pembrolizumab.
At a glance
| Generic name | Tinostamustinein |
|---|---|
| Sponsor | Royal Marsden NHS Foundation Trust |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tinostamustinein CI brief — competitive landscape report
- Tinostamustinein updates RSS · CI watch RSS
- Royal Marsden NHS Foundation Trust portfolio CI
Frequently asked questions about Tinostamustinein
What is Tinostamustinein?
Who makes Tinostamustinein?
What development phase is Tinostamustinein in?
Related
- Manufacturer: Royal Marsden NHS Foundation Trust — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing